These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 21138874)

  • 41. CD147 expression predicts biochemical recurrence after prostatectomy independent of histologic and pathologic features.
    Bauman TM; Ewald JA; Huang W; Ricke WA
    BMC Cancer; 2015 Jul; 15():549. PubMed ID: 26209327
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of an epithelial plasticity biomarker panel in men with localized prostate cancer.
    Armstrong AJ; Healy P; Halabi S; Vollmer R; Lark A; Kemeny G; Ware K; Freedland SJ
    Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):40-5. PubMed ID: 26458958
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The ratio of oleic-to-stearic acid in the prostate predicts biochemical failure after radical prostatectomy for localized prostate cancer.
    Kositsawat J; Flanigan RC; Meydani M; Choi YK; Freeman VL
    J Urol; 2007 Dec; 178(6):2391-6; discussion 2396. PubMed ID: 17936811
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
    Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
    J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Overexpression of the chromatin remodeler death-domain-associated protein in prostate cancer is an independent predictor of early prostate-specific antigen recurrence.
    Tsourlakis MC; Schoop M; Plass C; Huland H; Graefen M; Steuber T; Schlomm T; Simon R; Sauter G; Sirma H; Minner S
    Hum Pathol; 2013 Sep; 44(9):1789-96. PubMed ID: 23642739
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
    Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
    J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy.
    Moul JW
    Eur Urol; 1999; 35(5-6):399-407. PubMed ID: 10325496
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancer.
    Gannon PO; Lessard L; Stevens LM; Forest V; Bégin LR; Minner S; Tennstedt P; Schlomm T; Mes-Masson AM; Saad F
    Eur J Cancer; 2013 Jul; 49(10):2441-8. PubMed ID: 23541563
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer.
    Bauer JJ; Connelly RR; Seterhenn IA; Deausen J; Srivastava S; McLeod DG; Moul JW
    J Urol; 1998 Mar; 159(3):929-33. PubMed ID: 9474185
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cyr61 is regulated by cAMP-dependent protein kinase with serum levels correlating with prostate cancer aggressiveness.
    Terada N; Shiraishi T; Zeng Y; Mooney SM; Yeater DB; Mangold LA; Partin AW; Kulkarni P; Getzenberg RH
    Prostate; 2012 Jun; 72(9):966-76. PubMed ID: 22025384
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Thrombospondin-1 expression in patients with pathologic stage T3 prostate cancer undergoing radical prostatectomy: association with p53 alterations, tumor angiogenesis, and tumor progression.
    Grossfeld GD; Carroll PR; Lindeman N; Meng M; Groshen S; Feng AC; Hawes D; Cote RJ
    Urology; 2002 Jan; 59(1):97-102. PubMed ID: 11796289
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The significance of monoamine oxidase-A expression in high grade prostate cancer.
    Peehl DM; Coram M; Khine H; Reese S; Nolley R; Zhao H
    J Urol; 2008 Nov; 180(5):2206-11. PubMed ID: 18804811
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer.
    Zellweger T; Günther S; Zlobec I; Savic S; Sauter G; Moch H; Mattarelli G; Eichenberger T; Curschellas E; Rüfenacht H; Bachmann A; Gasser TC; Mihatsch MJ; Bubendorf L
    Int J Cancer; 2009 May; 124(9):2116-23. PubMed ID: 19117060
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prostate Cancer Antigen 3 Score Does Not Predict for Adverse Pathologic Features at Radical Prostatectomy or for Progression-free Survival in Clinically Localized, Intermediate- and High-risk Prostate Cancer.
    Hegde JV; Veruttipong D; Said JW; Reiter RE; Steinberg ML; King CR; Kishan AU
    Urology; 2017 Sep; 107():171-177. PubMed ID: 28552819
    [TBL] [Abstract][Full Text] [Related]  

  • 56. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology.
    Rubin MA; Mucci NR; Figurski J; Fecko A; Pienta KJ; Day ML
    Hum Pathol; 2001 Jul; 32(7):690-7. PubMed ID: 11486167
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multiple Tissue Biomarkers Independently and Additively Predict Prostate Cancer Pathology Outcomes.
    Cooperberg MR; Cowan JE; Lindquist KJ; Kobayashi Y; Simko JP; Bengtsson H; Singh K; Ngo V; Avila A; Newcomb LF; Tretriakova M; Lin DW; Stone S; Carroll PR; Paris PL
    Eur Urol; 2021 Jan; 79(1):141-149. PubMed ID: 33148472
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Radical prostatectomy and positive surgical margins: relationship with prostate cancer outcome.
    De La Roca RL; Da Cunha IW; Bezerra SM; Da Fonseca FP
    Int Braz J Urol; 2014; 40(3):306-15. PubMed ID: 25010296
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clusterin as a possible predictor for biochemical recurrence of prostate cancer following radical prostatectomy with intermediate Gleason scores: a preliminary report.
    Pins MR; Fiadjoe JE; Korley F; Wong M; Rademaker AW; Jovanovic B; Yoo TK; Kozlowski JM; Raji A; Yang XJ; Lee C
    Prostate Cancer Prostatic Dis; 2004; 7(3):243-8. PubMed ID: 15343364
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer.
    Rhodes DR; Sanda MG; Otte AP; Chinnaiyan AM; Rubin MA
    J Natl Cancer Inst; 2003 May; 95(9):661-8. PubMed ID: 12734317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.